23:59:40 EDT Tue 21 Mar 2023
Enter Symbol
or Name
USA
CA



News for U:PLRX from 2022-03-22 to 2023-03-21 - 37 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-03-13 08:01U:PLRXNews ReleasePliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
2023-03-09 16:05U:PLRXNews ReleasePliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
2023-03-08 16:01U:PLRXNews ReleasePliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
2023-03-01 08:01U:PLRXNews ReleasePliant Therapeutics to Participate in Upcoming Investor Events
2023-02-07 08:01U:PLRXNews ReleasePliant Therapeutics to Participate in Upcoming Investor Events
2023-02-02 08:02U:PLRXNews ReleasePliant Therapeutics Announces FDA Clearance of Investigational New Drug Application ‚  for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
2023-01-27 16:03U:PLRXNews ReleasePliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters ¢ € ™ Option to Purchase Additional Shares
2023-01-25 08:01U:PLRXNews ReleasePliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
2023-01-24 21:19U:PLRXNews ReleasePliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
2023-01-23 16:01U:PLRXNews ReleasePliant Therapeutics Announces Proposed Public Offering of Common Stock
2023-01-22 14:00U:PLRXNews ReleasePliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
2023-01-03 08:00U:PLRXNews ReleasePliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
2022-12-15 08:00U:PLRXNews ReleasePliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
2022-11-15 08:00U:PLRXNews ReleasePliant Therapeutics to Participate in Upcoming Investor Conferences
2022-11-08 16:02U:PLRXNews ReleasePliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
2022-10-05 08:00U:PLRXNews ReleasePliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
2022-09-15 08:00U:PLRXNews ReleasePliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
2022-09-01 08:00U:PLRXNews ReleasePliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
2022-08-30 08:00U:PLRXNews ReleasePliant Therapeutics to Participate in Upcoming Investor Conferences
2022-08-08 16:05U:PLRXNews ReleasePliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
2022-08-02 08:00U:PLRXNews ReleasePliant Therapeutics to Participate in BTIG Biotechnology Conference
2022-07-21 08:00U:PLRXNews ReleasePliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis
2022-07-15 16:03U:PLRXNews ReleasePliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
2022-07-12 19:46U:PLRXNews ReleasePliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering
2022-07-11 16:01U:PLRXNews ReleasePliant Therapeutics Announces Proposed Public Offering of Common Stock
2022-07-10 18:10U:PLRXNews ReleasePliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
2022-06-24 08:00U:PLRXNews ReleasePliant Therapeutics Announces Presentations at the International Liver Congress(TM) 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial
2022-06-22 08:00U:PLRXNews ReleasePliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies
2022-06-16 08:00U:PLRXNews ReleasePliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration
2022-06-15 16:01U:PLRXNews ReleasePliant Therapeutics Announces Presentations at the International Liver Congress(TM) 2022
2022-05-18 11:15U:PLRXNews ReleasePliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference
2022-05-11 08:00U:PLRXNews ReleasePliant Therapeutics to Participate in Upcoming Investor Conferences
2022-05-09 16:05U:PLRXNews ReleasePliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
2022-05-05 08:00U:PLRXNews ReleasePliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809
2022-05-03 08:00U:PLRXNews ReleasePliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
2022-05-02 08:00U:PLRXNews ReleasePliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference
2022-04-05 08:03U:PLRXNews ReleasePliant Therapeutics to Participate in Needham Healthcare Conference